Medical Scientists Are Investigating New Treatments For Insomnia
Did you know that one in three people will suffer from insomnia in their lifetime? Lack of sleep is no joke, quality of life and long term health. Sadly, the chances of suffering from insomnia increase with age. In fact, 40% to 60% of people over the age of 60 years old are insomniacs.
People with insomnia tend to experience daytime tiredness, fatigue or sleepiness. This places insomniacs at risk of accidental falls resulting from fatigue.
As a CureClick Ambassador, I wanted to tell you about an exciting new study that seeks to reduce insomnia symptoms in elderly people.
If you or a family member qualify for this clinical trial you may receive:
- payment up to $1250, depending on the study
- no cost, study related care from a local doctor
- no cost study medication
To learn more about this study, please visit the sponsor's website.
at least 55 years of age
For those of you whom are not familiar with clinical trials, here's some information that you can use:
What Are Clinical Trials?
Clinical trials are research studies to determine whether investigational drugs or treatments are safe and effective for humans.
All investigational devices and medicines must undergo several clinical trials, often times these clinical trials require thousands of people.
Why participate in a clinical trial?
People whom are eligible will have access to new investigational treatments that would be available to the general public only upon approval.
People whom are eligible for clinical trials will also receive study-related medical care and attention from clinical staff at research facilities.
Clinical trials offer hope for many people and gives researchers a chance to find better treatment for others in the future.
Disclaimer: I am not participating in this clinical trial. I am providing this information to my readers as a CureClick Ambasssador. Click on the links below to learn about my relationship with Cureclickand why I'm talking about clinical trials.
God made everything.
You can follow this conversation by subscribing to the comment feed for this post.